Organ Transplantation Market by Type of Organ (Heart Transplantation, Kidney Transplantation, Liver Transplantation), Product Type (Immunosuppressive Drugs, Organ Perfusion Systems, Preservation Solutions), Source of Organs, End-User - Global Forecast 202
Description
The Organ Transplantation Market was valued at USD 18.11 billion in 2024 and is projected to grow to USD 19.91 billion in 2025, with a CAGR of 10.57%, reaching USD 40.50 billion by 2032.
A concise orientation to current clinical advances, system integration, and operational priorities shaping modern organ transplantation practice
The landscape of organ transplantation is defined by rapid clinical innovation, evolving regulatory frameworks, and a growing emphasis on system-wide capacity to deliver equitable care. Advances in surgical techniques, preservation technologies, and immunomodulatory therapies have collectively improved patient outcomes and extended transplant candidacy, even as clinicians navigate complex comorbidity profiles and donor-recipient matching challenges. In parallel, health systems are reconfiguring care pathways to optimize coordination among donor services, transplant centers, and post-operative rehabilitation to reduce time-to-transplant and improve long-term graft survival.
Transitioning from episodic interventions to integrated care models requires robust data systems, standardized protocols, and cross-disciplinary collaboration. Moreover, the maturation of digital monitoring platforms and diagnostic tools creates opportunities for earlier detection of rejection and more personalized immunosuppression strategies. Moving forward, stakeholders must align clinical best practices with operational resilience and patient-centered support to translate technological and therapeutic progress into consistent population-level benefits. The opening section sets the scene for a detailed assessment of strategic inflection points shaping the field.
How recent technological breakthroughs, regulatory adaptations, and care delivery redesigns are collectively transforming the organ transplantation ecosystem
Significant shifts are reordering the organ transplantation environment, driven by technological breakthroughs and policy-level recalibration. Innovations in organ perfusion and preservation are extending viable transport windows and enabling marginal organs to be rehabilitated for transplantation. Concurrently, new classes of immunosuppressive agents and targeted biologics are changing post-transplant management by offering alternatives to longstanding regimens, thereby altering care pathways and long-term monitoring needs. As these therapeutic advances accelerate, they also bring different safety profiles and monitoring imperatives that must be integrated into clinical workflows.
Regulatory landscapes are adapting, with agencies accelerating pathways for device and biologic approvals, and payers increasingly scrutinizing real-world outcomes and value-based contracting. These dynamics incentivize closer partnerships between clinicians, device manufacturers, and diagnostics developers to demonstrate clinical utility and cost-effectiveness. Furthermore, digital health and telemonitoring are decentralizing follow-up care, enabling remote surveillance and earlier intervention for rejection or infection. Taken together, these transformative shifts are prompting providers and industry participants to rethink procurement, clinical trial design, and long-term patient engagement models to sustain improvements in survival and quality of life.
Assessing the operational and strategic consequences of United States tariff adjustments for procurement, supply resilience, and clinical continuity in transplantation
The imposition of new tariff measures in the United States has introduced a distinct set of operational and strategic considerations for transplant programs, device manufacturers, and supply chains. Increased import duties on critical devices, perfusion systems, and specialized preservation materials have the potential to raise procurement costs, prompting institutions to reassess sourcing strategies and inventory management to maintain continuity of care. These shifts create pressure for localized procurement, increased supplier diversification, and, in some cases, accelerated onshoring of key production activities to mitigate exposure to tariff-driven cost volatility.
Importantly, tariffs also influence procurement timelines and contractual negotiations as buyers seek predictable pricing and supply guarantees. In response, manufacturers and distributors may need to revise commercial models, offer bundled services, or adopt risk-sharing arrangements to preserve adoption momentum for advanced technologies. At the clinical level, transplant centers must balance cost containment with the imperative to maintain access to the latest preservation and monitoring technologies that support clinical outcomes. Consequently, cross-functional planning across clinical leadership, procurement, and finance becomes essential to absorb tariff impacts while safeguarding patient care pathways.
Translating organ type, product category, donor source, and care setting segmentation into actionable insights for clinical and commercial strategy
Insightful segmentation analysis reveals where clinical needs intersect with commercial opportunity and service delivery imperatives. When examining organ type, the field spans Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation, and Pancreas Transplantation, each with distinct clinical workflows, donor availability challenges, and device or therapy dependencies. For example, heart and lung transplantation are tightly linked to advanced organ perfusion and rapid transport solutions, whereas kidney and liver programs place differing emphasis on immunosuppressive regimens and long-term follow-up strategies.
Looking through the lens of product type uncovers differentiated demand drivers across Immunosuppressive Drugs, Organ Perfusion Systems, Preservation Solutions, Surgical Instruments & Accessories, and Transplant Diagnostics & Monitoring. Preservation and perfusion technologies directly influence organ viability and utilization, while diagnostics and monitoring shape post-operative management and outcomes measurement. Considering source-of-organ dynamics, the distinction between Deceased and Living donations informs allocation pathways, ethical considerations, and donor management protocols that affect operational throughput. Finally, end-user segmentation across Ambulatory Surgical Centers, Hospitals, and Transplantation Centers highlights variations in infrastructure, staffing models, and capacity to adopt complex technologies. Together, these segmentation dimensions provide a practical framework to prioritize development, commercialization, and implementation strategies tailored to specific clinical and care-delivery contexts.
Regional dynamics that determine adoption patterns, infrastructure needs, and strategic priorities across the Americas, EMEA, and Asia-Pacific markets
Regional dynamics materially influence clinical practice patterns, reimbursement approaches, and the pace of technology adoption. In the Americas, established transplant networks and high procedural volumes coexist with persistent disparities in access that drive initiatives aimed at improving donor registries, expanding living donation programs, and integrating telehealth for follow-up care. Regional policy debates around pricing and reimbursement can shape procurement cycles and the commercial viability of advanced preservation systems and diagnostics.
In Europe, Middle East & Africa, regulatory heterogeneity and variable infrastructure capacity create a mosaic of adoption pathways. Some markets within the region are early adopters of perfusion technologies and sophisticated monitoring platforms, while others remain focused on strengthening basic transplantation infrastructure and workforce training. Cross-border referrals and regional centers of excellence play a vital role in balancing capacity and expertise. Across Asia-Pacific, rapid investment in tertiary care capacity and growing organ donation initiatives are expanding transplant activity, with several health systems actively exploring domestic manufacturing and public-private partnerships to support supply chain resilience. Collectively, these regional considerations inform differentiated go-to-market approaches and prioritize where capacity building or regulatory engagement will yield the greatest impact.
Competitive and collaborative forces driving innovation, commercialization, and service-led adoption among enterprises active in transplantation solutions
Competitive dynamics in transplantation are shaped by firms that combine clinical expertise with capabilities in device engineering, biologics development, and diagnostics integration. Leading participants are investing in R&D to optimize organ preservation platforms, refine immunomodulatory regimens, and embed digital monitoring into perioperative pathways. Strategic partnerships between device developers and diagnostic laboratories are increasingly common, enabling integrated solutions that link organ viability assessment to downstream patient monitoring. Additionally, service-oriented models that bundle equipment, training, and maintenance are gaining traction as buyers seek to reduce implementation barriers and ensure consistent performance across multiple centers.
Mergers, acquisitions, and licensing agreements remain important mechanisms to accelerate access to complementary technologies and expand geographic reach. At the same time, specialty clinical centers and academic consortia continue to drive translational research, feeding evidence into regulatory submissions and payer dialogues. For companies seeking to differentiate, the ability to demonstrate real-world effectiveness, provide clinician training, and support long-term patient follow-up are critical capabilities that influence adoption among transplant programs. Stakeholders that align product development with implementation support and robust clinical evidence will be better positioned to meet evolving provider requirements.
Actionable strategic priorities for industry leaders to align clinical innovation, supply resilience, and evidence generation to maximize adoption and impact
Industry leaders should pursue a multi-pronged strategy that aligns clinical value, operational resilience, and payer engagement to accelerate impact. First, prioritize development and validation of technologies that demonstrably improve organ viability and reduce perioperative risk, while simultaneously investing in clinician training and implementation support to shorten adoption cycles. This dual focus on product performance and deployment readiness will help bridge the gap between innovation and routine clinical use. Next, diversify supply chains and consider regional manufacturing or strategic stocking arrangements to mitigate tariff and import-related disruptions, while negotiating outcome-based procurement agreements where feasible to share risk with buyers.
Further, organizations should deepen collaborations with transplant centers and academic partners to generate high-quality real-world evidence that supports regulatory and reimbursement discussions. Embrace digital platforms that enable remote monitoring and patient engagement, thereby improving post-transplant surveillance and adherence to immunosuppressive therapy. Finally, adopt a patient-centered communication strategy that addresses access barriers and equity considerations, ensuring that technological advances translate into broader population benefits. These combined actions will strengthen market positioning and support sustainable improvements in clinical outcomes.
A mixed-methods research framework combining frontline clinical input, systematic literature review, and commercial validation to produce robust, actionable insights
The research approach integrates a triangular methodology combining primary qualitative inquiry, systematic secondary intelligence gathering, and cross-validation through expert consultation. Primary efforts comprised structured interviews and advisory sessions with transplant surgeons, procurement leaders, perfusion specialists, and transplant pharmacists to capture frontline operational realities, clinical adoption barriers, and unmet technology needs. These qualitative inputs were augmented by a rigorous review of peer-reviewed clinical literature, regulatory guidance documents, and real-world evidence studies to contextualize clinical efficacy, safety considerations, and standard-of-care evolution.
To ensure robustness, findings were triangulated with supply chain and commercial intelligence gathered from manufacturers, distributors, and hospital procurement stakeholders. The methodology prioritized transparency in data provenance and applied thematic synthesis to distill actionable insights. Where data gaps were identified, targeted expert consultations validated assumptions and refined interpretation. This mixed-methods framework supports a pragmatic synthesis of clinical, regulatory, and operational dimensions that inform decision-making without relying on single-source estimates.
A synthesis of clinical progress, operational imperatives, and collaborative levers necessary to convert innovation into equitable, sustained transplantation improvements
In summary, the field of organ transplantation sits at an inflection point where clinical innovation, supply chain dynamics, and regulatory evolution converge to create both opportunity and complexity. Advances in preservation, perfusion, and targeted therapeutics are enabling better outcomes, yet their full potential depends on thoughtful implementation, resilient procurement practices, and compelling real-world evidence. Tariff-related shifts and regional heterogeneity further underscore the need for adaptive commercial strategies and localized capacity building to ensure access to critical technologies.
Ultimately, success will be measured by the ability of stakeholders to integrate technological advances into reliable care pathways that are accessible and sustainable. By focusing on collaborative evidence generation, supply chain diversification, and patient-centered deployment, clinicians, industry participants, and policymakers can work together to expand access, improve graft survival, and enhance quality of life for transplant recipients. The concluding perspective emphasizes the importance of coordinated action to translate innovation into consistent improvements across diverse care settings.
Please Note: PDF & Excel + Online Access - 1 Year
A concise orientation to current clinical advances, system integration, and operational priorities shaping modern organ transplantation practice
The landscape of organ transplantation is defined by rapid clinical innovation, evolving regulatory frameworks, and a growing emphasis on system-wide capacity to deliver equitable care. Advances in surgical techniques, preservation technologies, and immunomodulatory therapies have collectively improved patient outcomes and extended transplant candidacy, even as clinicians navigate complex comorbidity profiles and donor-recipient matching challenges. In parallel, health systems are reconfiguring care pathways to optimize coordination among donor services, transplant centers, and post-operative rehabilitation to reduce time-to-transplant and improve long-term graft survival.
Transitioning from episodic interventions to integrated care models requires robust data systems, standardized protocols, and cross-disciplinary collaboration. Moreover, the maturation of digital monitoring platforms and diagnostic tools creates opportunities for earlier detection of rejection and more personalized immunosuppression strategies. Moving forward, stakeholders must align clinical best practices with operational resilience and patient-centered support to translate technological and therapeutic progress into consistent population-level benefits. The opening section sets the scene for a detailed assessment of strategic inflection points shaping the field.
How recent technological breakthroughs, regulatory adaptations, and care delivery redesigns are collectively transforming the organ transplantation ecosystem
Significant shifts are reordering the organ transplantation environment, driven by technological breakthroughs and policy-level recalibration. Innovations in organ perfusion and preservation are extending viable transport windows and enabling marginal organs to be rehabilitated for transplantation. Concurrently, new classes of immunosuppressive agents and targeted biologics are changing post-transplant management by offering alternatives to longstanding regimens, thereby altering care pathways and long-term monitoring needs. As these therapeutic advances accelerate, they also bring different safety profiles and monitoring imperatives that must be integrated into clinical workflows.
Regulatory landscapes are adapting, with agencies accelerating pathways for device and biologic approvals, and payers increasingly scrutinizing real-world outcomes and value-based contracting. These dynamics incentivize closer partnerships between clinicians, device manufacturers, and diagnostics developers to demonstrate clinical utility and cost-effectiveness. Furthermore, digital health and telemonitoring are decentralizing follow-up care, enabling remote surveillance and earlier intervention for rejection or infection. Taken together, these transformative shifts are prompting providers and industry participants to rethink procurement, clinical trial design, and long-term patient engagement models to sustain improvements in survival and quality of life.
Assessing the operational and strategic consequences of United States tariff adjustments for procurement, supply resilience, and clinical continuity in transplantation
The imposition of new tariff measures in the United States has introduced a distinct set of operational and strategic considerations for transplant programs, device manufacturers, and supply chains. Increased import duties on critical devices, perfusion systems, and specialized preservation materials have the potential to raise procurement costs, prompting institutions to reassess sourcing strategies and inventory management to maintain continuity of care. These shifts create pressure for localized procurement, increased supplier diversification, and, in some cases, accelerated onshoring of key production activities to mitigate exposure to tariff-driven cost volatility.
Importantly, tariffs also influence procurement timelines and contractual negotiations as buyers seek predictable pricing and supply guarantees. In response, manufacturers and distributors may need to revise commercial models, offer bundled services, or adopt risk-sharing arrangements to preserve adoption momentum for advanced technologies. At the clinical level, transplant centers must balance cost containment with the imperative to maintain access to the latest preservation and monitoring technologies that support clinical outcomes. Consequently, cross-functional planning across clinical leadership, procurement, and finance becomes essential to absorb tariff impacts while safeguarding patient care pathways.
Translating organ type, product category, donor source, and care setting segmentation into actionable insights for clinical and commercial strategy
Insightful segmentation analysis reveals where clinical needs intersect with commercial opportunity and service delivery imperatives. When examining organ type, the field spans Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation, and Pancreas Transplantation, each with distinct clinical workflows, donor availability challenges, and device or therapy dependencies. For example, heart and lung transplantation are tightly linked to advanced organ perfusion and rapid transport solutions, whereas kidney and liver programs place differing emphasis on immunosuppressive regimens and long-term follow-up strategies.
Looking through the lens of product type uncovers differentiated demand drivers across Immunosuppressive Drugs, Organ Perfusion Systems, Preservation Solutions, Surgical Instruments & Accessories, and Transplant Diagnostics & Monitoring. Preservation and perfusion technologies directly influence organ viability and utilization, while diagnostics and monitoring shape post-operative management and outcomes measurement. Considering source-of-organ dynamics, the distinction between Deceased and Living donations informs allocation pathways, ethical considerations, and donor management protocols that affect operational throughput. Finally, end-user segmentation across Ambulatory Surgical Centers, Hospitals, and Transplantation Centers highlights variations in infrastructure, staffing models, and capacity to adopt complex technologies. Together, these segmentation dimensions provide a practical framework to prioritize development, commercialization, and implementation strategies tailored to specific clinical and care-delivery contexts.
Regional dynamics that determine adoption patterns, infrastructure needs, and strategic priorities across the Americas, EMEA, and Asia-Pacific markets
Regional dynamics materially influence clinical practice patterns, reimbursement approaches, and the pace of technology adoption. In the Americas, established transplant networks and high procedural volumes coexist with persistent disparities in access that drive initiatives aimed at improving donor registries, expanding living donation programs, and integrating telehealth for follow-up care. Regional policy debates around pricing and reimbursement can shape procurement cycles and the commercial viability of advanced preservation systems and diagnostics.
In Europe, Middle East & Africa, regulatory heterogeneity and variable infrastructure capacity create a mosaic of adoption pathways. Some markets within the region are early adopters of perfusion technologies and sophisticated monitoring platforms, while others remain focused on strengthening basic transplantation infrastructure and workforce training. Cross-border referrals and regional centers of excellence play a vital role in balancing capacity and expertise. Across Asia-Pacific, rapid investment in tertiary care capacity and growing organ donation initiatives are expanding transplant activity, with several health systems actively exploring domestic manufacturing and public-private partnerships to support supply chain resilience. Collectively, these regional considerations inform differentiated go-to-market approaches and prioritize where capacity building or regulatory engagement will yield the greatest impact.
Competitive and collaborative forces driving innovation, commercialization, and service-led adoption among enterprises active in transplantation solutions
Competitive dynamics in transplantation are shaped by firms that combine clinical expertise with capabilities in device engineering, biologics development, and diagnostics integration. Leading participants are investing in R&D to optimize organ preservation platforms, refine immunomodulatory regimens, and embed digital monitoring into perioperative pathways. Strategic partnerships between device developers and diagnostic laboratories are increasingly common, enabling integrated solutions that link organ viability assessment to downstream patient monitoring. Additionally, service-oriented models that bundle equipment, training, and maintenance are gaining traction as buyers seek to reduce implementation barriers and ensure consistent performance across multiple centers.
Mergers, acquisitions, and licensing agreements remain important mechanisms to accelerate access to complementary technologies and expand geographic reach. At the same time, specialty clinical centers and academic consortia continue to drive translational research, feeding evidence into regulatory submissions and payer dialogues. For companies seeking to differentiate, the ability to demonstrate real-world effectiveness, provide clinician training, and support long-term patient follow-up are critical capabilities that influence adoption among transplant programs. Stakeholders that align product development with implementation support and robust clinical evidence will be better positioned to meet evolving provider requirements.
Actionable strategic priorities for industry leaders to align clinical innovation, supply resilience, and evidence generation to maximize adoption and impact
Industry leaders should pursue a multi-pronged strategy that aligns clinical value, operational resilience, and payer engagement to accelerate impact. First, prioritize development and validation of technologies that demonstrably improve organ viability and reduce perioperative risk, while simultaneously investing in clinician training and implementation support to shorten adoption cycles. This dual focus on product performance and deployment readiness will help bridge the gap between innovation and routine clinical use. Next, diversify supply chains and consider regional manufacturing or strategic stocking arrangements to mitigate tariff and import-related disruptions, while negotiating outcome-based procurement agreements where feasible to share risk with buyers.
Further, organizations should deepen collaborations with transplant centers and academic partners to generate high-quality real-world evidence that supports regulatory and reimbursement discussions. Embrace digital platforms that enable remote monitoring and patient engagement, thereby improving post-transplant surveillance and adherence to immunosuppressive therapy. Finally, adopt a patient-centered communication strategy that addresses access barriers and equity considerations, ensuring that technological advances translate into broader population benefits. These combined actions will strengthen market positioning and support sustainable improvements in clinical outcomes.
A mixed-methods research framework combining frontline clinical input, systematic literature review, and commercial validation to produce robust, actionable insights
The research approach integrates a triangular methodology combining primary qualitative inquiry, systematic secondary intelligence gathering, and cross-validation through expert consultation. Primary efforts comprised structured interviews and advisory sessions with transplant surgeons, procurement leaders, perfusion specialists, and transplant pharmacists to capture frontline operational realities, clinical adoption barriers, and unmet technology needs. These qualitative inputs were augmented by a rigorous review of peer-reviewed clinical literature, regulatory guidance documents, and real-world evidence studies to contextualize clinical efficacy, safety considerations, and standard-of-care evolution.
To ensure robustness, findings were triangulated with supply chain and commercial intelligence gathered from manufacturers, distributors, and hospital procurement stakeholders. The methodology prioritized transparency in data provenance and applied thematic synthesis to distill actionable insights. Where data gaps were identified, targeted expert consultations validated assumptions and refined interpretation. This mixed-methods framework supports a pragmatic synthesis of clinical, regulatory, and operational dimensions that inform decision-making without relying on single-source estimates.
A synthesis of clinical progress, operational imperatives, and collaborative levers necessary to convert innovation into equitable, sustained transplantation improvements
In summary, the field of organ transplantation sits at an inflection point where clinical innovation, supply chain dynamics, and regulatory evolution converge to create both opportunity and complexity. Advances in preservation, perfusion, and targeted therapeutics are enabling better outcomes, yet their full potential depends on thoughtful implementation, resilient procurement practices, and compelling real-world evidence. Tariff-related shifts and regional heterogeneity further underscore the need for adaptive commercial strategies and localized capacity building to ensure access to critical technologies.
Ultimately, success will be measured by the ability of stakeholders to integrate technological advances into reliable care pathways that are accessible and sustainable. By focusing on collaborative evidence generation, supply chain diversification, and patient-centered deployment, clinicians, industry participants, and policymakers can work together to expand access, improve graft survival, and enhance quality of life for transplant recipients. The concluding perspective emphasizes the importance of coordinated action to translate innovation into consistent improvements across diverse care settings.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
198 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Development of ex vivo machine perfusion techniques to significantly extend organ viability times
- 5.2. Rapid advancements in genetically engineered pig organ xenotransplantation for human recipients
- 5.3. Emergence of clinical-grade 3D bioprinted organ scaffolds seeded with patient-derived cells
- 5.4. Expansion of kidney paired donation chains enabled by AI-driven donor-recipient matching algorithms
- 5.5. Adoption of normothermic regional perfusion in donation after circulatory death protocols to improve graft outcomes
- 5.6. Implementation of hypothermic oxygenated perfusion (HOPE) to reduce liver graft reperfusion injury rates in transplants
- 5.7. Regulatory advancements for stem cell-derived organoids clearing pathways toward first-in-human transplantation trials
- 5.8. Integration of telehealth care platforms for remote monitoring and management of transplant patients post-surgery
- 5.9. Utilization of blockchain-enabled organ tracking systems to enhance transparency and traceability in transplantation logistics
- 5.10. Deployment of predictive analytics powered by machine learning to optimize organ allocation and reduce waitlist mortality
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Organ Transplantation Market, by Type of Organ
- 8.1. Heart Transplantation
- 8.2. Kidney Transplantation
- 8.3. Liver Transplantation
- 8.4. Lung Transplantation
- 8.5. Pancreas Transplantation
- 9. Organ Transplantation Market, by Product Type
- 9.1. Immunosuppressive Drugs
- 9.2. Organ Perfusion Systems
- 9.3. Preservation Solutions
- 9.4. Surgical Instruments & Accessories
- 9.5. Transplant Diagnostics & Monitoring
- 10. Organ Transplantation Market, by Source of Organs
- 10.1. Deceased
- 10.2. Living
- 11. Organ Transplantation Market, by End-User
- 11.1. Ambulatory Surgical Centers
- 11.2. Hospitals
- 11.3. Transplantation Centers
- 12. Organ Transplantation Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Organ Transplantation Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Organ Transplantation Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. 21st Century Medicine
- 15.3.2. Abbott Laboratories
- 15.3.3. AbbVie Inc.
- 15.3.4. Astellas Pharma Inc.
- 15.3.5. Bio-Rad Laboratories, Inc.
- 15.3.6. BiolifeSolutions, Inc.
- 15.3.7. Bridge to Life Ltd.
- 15.3.8. Bristol-Myers Squibb Company
- 15.3.9. CHIESI Farmaceutici S.p.A.
- 15.3.10. Dr. Franz Kohler Chemie GmbH
- 15.3.11. eGenesis Inc.
- 15.3.12. F. Hoffmann-La Roche Ltd
- 15.3.13. Illumina, Inc.
- 15.3.14. Medtronic PLC
- 15.3.15. Novartis AG
- 15.3.16. Organ Recovery Systems, Inc.
- 15.3.17. Organovo, Inc.
- 15.3.18. OrganOx Limited
- 15.3.19. Pfizer Inc.
- 15.3.20. Plexision, Inc.
- 15.3.21. Preservation Solutions, Inc.
- 15.3.22. Sanofi S.A.
- 15.3.23. Stryker Corporation
- 15.3.24. Terumo Corporation
- 15.3.25. Teva Pharmaceuticals Industries Ltd.
- 15.3.26. Thermo Fisher Scientific Inc.
- 15.3.27. TransMedics Group, Inc.
- 15.3.28. United Therapeutics Corporation
- 15.3.29. Veloxis Pharmaceuticals, Inc. by Asahi Kasei Corp.
- 15.3.30. Vivalyx GmbH
- 15.3.31. Xvivo Perfusion AB
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
